Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 8/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30602435 | 1.00 | HPGD (0.60) | HPGDKMT2AL3MBTL1GLAHSD17B10 | |
| SCHEMBL15020081 | 0.97 | HPGD (0.64) | HPGDKMT2AL3MBTL1GLAHSD17B10 | |
| SCHEMBL9996874 | 0.88 | POLB (0.63) | HPGDKMT2AL3MBTL1GLATSHR | |
| SCHEMBL789725 | 0.87 | KMT2A (0.80) | HPGDKMT2AL3MBTL1GLAALDH1A1 | |
| SCHEMBL15021744 | 0.86 | KMT2A (0.55) | HPGDKMT2AL3MBTL1GLAHSD17B10 | |
| SCHEMBL9997035 | 0.86 | KMT2A (0.55) | HPGDKMT2AL3MBTL1GLAALDH1A1 | |
| SCHEMBL12068505 | 0.86 | GLA (0.55) | HPGDKMT2AL3MBTL1GLAHSD17B10 | |
| SCHEMBL19869974 | 0.83 | KMT2A (0.55) | HPGDKMT2AL3MBTL1GLAALDH1A1 | |
| SCHEMBL9996943 | 0.82 | GLA (0.51) | HPGDKMT2AL3MBTL1GLAHSD17B10 | |
| SCHEMBL9996788 | 0.82 | GLA (0.51) | HPGDKMT2AL3MBTL1GLAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834449-B2 | TYK2 inhibitors and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-12-05 | — | — | US | disclosed |
| US-11834449-B2 | TYK2 inhibitors and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-12-05 | — | — | US | disclosed |
| WO-2020112937-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2020-06-04 | — | — | WO | disclosed |
| US-20170342064-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-11-30 | — | — | US | disclosed |
| EP-3230285-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER | Bayer Pharma Aktiengesellschaft (DE) | 2017-10-18 | — | — | EP | disclosed |
| US-9663510-B2 | Substituted triazolopyridines and their use as TTK inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-05-30 | — | — | US | disclosed |
| US-9663510-B2 | Substituted triazolopyridines and their use as TTK inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-05-30 | — | — | US | disclosed |
| US-9663510-B2 | Substituted triazolopyridines and their use as TTK inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-05-30 | — | — | US | disclosed |
| EP-3008062-B1 | PRODRUG DERIVATIVES OF SUBSTITUTED TRIAZOLOPYRIDINES | Bayer Pharma AG (DE) | 2017-04-05 | — | — | EP | disclosed |
| EP-3008062-B1 | PRODRUG DERIVATIVES OF SUBSTITUTED TRIAZOLOPYRIDINES | Bayer Pharma AG (DE) | 2017-04-05 | — | — | EP | disclosed |
| WO-2014009219-A1 | METHOD FOR PREPARING SUBSTITUTED TRIAZOLOPYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-01-16 | — | — | WO | disclosed |
| WO-2013087579-A1 | SUBSTITUTED TRIAZOLOPYRIDINES AND THEIR USE AS TTK INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-20 | — | — | WO | disclosed |
| US-20130156756-A1 | Substituted Triazolopyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130156756-A1 | Substituted Triazolopyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| WO-2013087579-A1 | SUBSTITUTED TRIAZOLOPYRIDINES AND THEIR USE AS TTK INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-20 | — | — | WO | disclosed |
| US-20130156756-A1 | Substituted Triazolopyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| EP-2582699-A1 | SUBSTITUTED TRIAZOLOPYRIDINES | Bayer Intellectual Property GmbH (DE) | 2013-04-24 | — | — | EP | disclosed |
| WO-2012160029-A1 | SUBSTITUTED TRIAZOLOPYRIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-11-29 | — | — | WO | disclosed |
| WO-2011157688-A1 | SUBSTITUTED TRIAZOLOPYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011157688-A1 | SUBSTITUTED TRIAZOLOPYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834449-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | HPGD 4476/4885KMT2A 206/4885L3MBTL1 914/4885 |
| US-20130156756-A1 | Substituted Triazolopyridines | CCND2, CCND1, QDPR | HPGD 1247/4885KMT2A 3323/4885L3MBTL1 2924/4885 |
| US-20170342064-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER | MPST, TK1, BRCA1 | HPGD 1563/4885KMT2A 3222/4885L3MBTL1 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.